Odyssey Therapeutics to present additional Phase 2a OD-001 ulcerative colitis data at UEG Week 2026
ODTX•Odyssey Therapeutics plans to present additional Phase 2a induction data for OD-001 in moderate to severe ulcerative colitis at UEG Week 2026 in Barcelona on Oct. 20. The presentation will cover safety and signs of clinical benefit, with a conference call and webcast set to discuss further data.
1. Planned data presentation
Odyssey Therapeutics said it will present additional Phase 2a induction results for OD-001 in moderate to severe ulcerative colitis at UEG Week 2026 in Barcelona on Oct. 20. The presentation is set to cover the study’s safety profile and signs of clinical benefit.
2. Conference call
A conference call and webcast on Oct. 20 will discuss additional induction data beyond what is shown at the meeting.
